TSPO receptors are peripheral benzodiazepine receptors (PBDRs). Unlike central benzodiazepine receptors (CBDRs), PBDRs (TSPO receptors) are widely presented in organs and tissues of animals and humans; these receptors are involved significantly in the regulation of many physiological processes in the norm and pathologies. Elucidation of the molecular bases of interactions between the TSPO receptors and their ligands is an important task of modern pharmacochemistry. We studied the anxiolytic properties of some derivatives of 1-methoxycarbonylmethyl-3-arylamino-7-bromo-5-phenyl-1, 2-dihydro-3H-1,4-benzodiazepin-2-one (compounds 1-7), which demonstrate considerable affinity for TSPO and CBDRs. The anxiolytic activity was estimated in experiments on rats in the “Conflict situation” test, while the intensity of motor activity was estimated in the standard “Open field” test. All tested compounds demonstrated a rather high selectivity in binding with TSPO receptors; compounds 1–4 manifested significant anxiolytic properties. Compound 2 demonstrated the maximum anxiolytic activity; after binding with TSPO receptors, Ki(TSPO) = 19, while Ki(CBDRs) > 10000 nM. All studied compounds were characterized by low toxicity; their LD50 exceeded 500 mg/kg.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
A. M. Barron, L. M. Garcia-Segura, D. Caruso, et al., “Ligand for translocator protein reverses pathology in a mouse model of Alzheimer’s disease,” J. Neurosci., 33, No. 20, 8891-8897 (2013).
F. Fares, S. Bar-Ami, J. M. Brandes, and M. Gavish, “Gonadotropin- and estrogen-induced increase of peripheral-type benzodiazepine binding sites in the hypophyseal-genital axis of rats,” Eur. J. Pharmacol., 133, No. 1, 97-105 (1987).
J. Benavides, D. Quateronet, F. Imbault, et al., “Labelling of ‘peripheral-type’ benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: kinetic studies and autoсradiographic localization,” J. Neurochem., 41, 1744-1750 (1983).
H. Yamagishi, M. Watanabe, K. Yazaki, et al., “Pharmacological characterization of an 18-kDa protein associated with the peripheral-type benzodiazepine receptor in salivary glands,” Jpn. J. Pharmacol., 82, No. 2, 110-118 (2000).
M. Gavish, I. Bachman., R. Shouknm, et al., “Enigma of the peripheral benzodiazepine receptor,” Pharmacol. Rev., 51, No. 4, 629-233 (1999).
M. Gavish and R. Weizman, “Role of peripheral-type benzodiazepine receptors in steroidogenesis,” Clin. Neuropharmacol., 20, No. 6, 473-182 (1997).
N. Burenkova, V. Pavlovsky, I. Oleinich, et al., “Synthesis and selectivity of 1-methoxycarbonylmethyl-3-arylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-ones binding for CNS benzodiazepine receptors,” Ukr. Bioorgan. Acta, No. 1, 8-15 (2009).
S. A. Andronati, G. Ya. Avrutskii, T. A. Voronina, et al., in: Phenazepam [in Russian], A. V. Bogatskii (ed.), Naukova Dumka, Kyiv (1982), pp. 288.
V. V. Gatsura, Techniques for Primary Pharmacological Study of Biologically Active Substances [in Russian], Nauka, Moscow (1974).
S. A. Andronati, T. A. Voronina, N, Ya. Golovenko, et al., in: Gidazepam [in Russian], S. A. Andronati (ed.), Naukova Dumka, Kyiv (1992), pp. 200.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Andronati, S.A., Karaseva, T.L. & Zamkovaya, A.V. Anxiolytic Properties of Derivatives of 1-Methoxycarbonylmethyl-3-Arylamino-7-Bromo-5-Phenyl-1,2-Dihydro-3H-1,4-Benzodiazepin-2-one. Neurophysiology 49, 165–167 (2017). https://doi.org/10.1007/s11062-017-9648-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11062-017-9648-4